On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based...
Researchers at the University of Tokyo have developed a streamlined CRISPR-Cas9-based method that enables efficient replacement of entire mouse gene...
Researchers in Japan have developed a CRISPR-Cas-based system to edit epigenetic marks in mouse sperm, enabling direct investigation of whether DNA...
nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
American researchers have developed an RNA-based platform that uses CRISPR epigenetic editors to durably silence or activate genes in primary human T...
Researchers have developed a compact, all-in-one CRISPR-dCas9-based repressor platform delivered via AAV, effectively silencing gene expression...
Korean researchers have developed programmable conditional guide RNAs for precise control of endogenous gene expression using the CRISPR-Cas system....
In a recent study, researchers in Italy addressed the critical need for experimental validation of durable epigenetic silencing after transient...
